BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Amgen (AMGN) Drug Cuts Bad Cholesterol Up to 66 Pct in Patients - Trial


11/6/2012 6:34:28 AM

Amgen Inc. (AMGN), the world’s largest biotechnology company, said its experimental heart drug lowered cholesterol levels in patients unable to take standard medicines such as Pfizer Inc.’s Lipitor because of side effects. The drug, AMG-145, which targets cholesterol-regulating gene PCSK9 in the liver, reduced LDL, or bad cholesterol, 51 percent in patients intolerant to medicines like Lipitor, called statins, after 12 weeks, and 63 percent among those taking it in combination with Merck & Co.’s (MRK) cholesterol treatment Zetia, according to a study presented today at the American Heart Association meeting in Los Angeles. Amgen is focusing on the drug’s potential to help offset declining sales of its anemia drugs Aranesp and Epogen, which together will generate $4 billion in estimated sales this year and face increased competition by 2015. The Thousand Oaks, California-based company is competing with some of the world’s biggest drugmakers, such as Pfizer, Roche Holding AG (ROG) and Sanofi (SAN), to be first to market with the new cholesterol medicine.



Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->